APA (7th ed.) Citation

R, W., A, H., C, B., S, H., AL, I., F, B., . . . U, K. (2024). CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin. Nuclear medicine, 63(2), 57. https://doi.org/10.1055/a-2194-9965

Chicago Style (17th ed.) Citation

R, Werner, et al. "CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges." Nuklearmedizin. Nuclear Medicine 63, no. 2 (2024): 57. https://doi.org/10.1055/a-2194-9965.

MLA (9th ed.) Citation

R, Werner, et al. "CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges." Nuklearmedizin. Nuclear Medicine, vol. 63, no. 2, 2024, p. 57, https://doi.org/10.1055/a-2194-9965.